Jama Author Interviews: Covering Research In Medicine, Science, & Clinical Practice. For Physicians, Researchers, & Clinician
Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:03:39
- Mas informaciones
Informações:
Sinopsis
Interview with Dhruv S. Kazi, MD, MSc, MS, author of Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
